1
|
Fung A, Collins RA. Editorial. Hong Kong Med J 2024; 30 Suppl 1:3. [PMID: 38413203] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/29/2024] Open
Affiliation(s)
- A Fung
- Head, Research and Data Analytics Office, Health Bureau
| | - R A Collins
- Senior Scientific Reviewer, Research and Data Analytics Office, Health Bureau
| |
Collapse
|
2
|
Fung A, Collins RA. Editorial. Hong Kong Med J 2023; 29 Suppl 7:3. [PMID: 38148647] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2023] Open
Affiliation(s)
- A Fung
- Head, Research and Data Analytics Office, Health Bureau
| | - R A Collins
- Senior Scientific Reviewer, Research and Data Analytics Office, Health Bureau
| |
Collapse
|
3
|
Fung A, Collins RA. Editorial. Hong Kong Med J 2023; 29 Suppl 4:3. [PMID: 37690797] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/12/2023] Open
Affiliation(s)
- A Fung
- Head, Research Office, Health Bureau
| | - R A Collins
- Senior Scientific Reviewer, Research Office, Health Bureau
| |
Collapse
|
4
|
Fung A, Collins RA. Editorial. Hong Kong Med J 2023; 29 Suppl 3:3. [PMID: 37357581] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/27/2023] Open
Affiliation(s)
- A Fung
- Head, Research Office, Health Bureau
| | - R A Collins
- Senior Scientific Reviewer, Research Office, Health Bureau
| |
Collapse
|
5
|
Fung A, Collins RA. Editorial. Hong Kong Med J 2023; 29 Suppl 2:3. [PMID: 36950995] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/24/2023] Open
Affiliation(s)
- A Fung
- Head, Research Office, Health Bureau
| | - R A Collins
- Senior Scientific Reviewer, Research Office, Health Bureau
| |
Collapse
|
6
|
Fung A, Collins RA. Editorial. Hong Kong Med J 2023; 29 Suppl 1:3. [PMID: 36919208] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/16/2023] Open
Affiliation(s)
- A Fung
- Head, Research Office, Health Bureau
| | - R A Collins
- Senior Scientific Reviewer, Research Office, Health Bureau
| |
Collapse
|
7
|
Heritage SR, Lynch-Kelly K, Kalvala J, Tulloch R, Devasar A, Harewood J, Khoury E, Abdelwahed A, Fung A, Bigogno CM, Gray R, Keshwara S, Joseph PJS, Selby P, Tharmalingam H. Medical Student Perspectives on Undergraduate Oncology Education in the UK. Clin Oncol (R Coll Radiol) 2022; 34:e355-e364. [PMID: 35595594 DOI: 10.1016/j.clon.2022.04.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2022] [Revised: 03/31/2022] [Accepted: 04/27/2022] [Indexed: 11/03/2022]
Abstract
AIMS The British Oncology Network for Undergraduate Societies (BONUS) surveyed students who attended an oncology revision day to determine their views on the current quantity, quality and type of curriculum-based oncology teaching they have experienced. MATERIALS AND METHODS Students attending two BONUS revision days received a questionnaire assessing their experience of oncology teaching within the medical curriculum and interest in pursuing a future career in oncology using a 10-point Likert scale. Data were collected with informed consent to be anonymised and used for research. Student demographics and qualitative and quantitative data about experiences of oncology education were analysed. RESULTS In total, 451 students registered to attend the revision days. After removal of duplicates, non-responders and non-UK participants, responses from 153 students studying across years 1-6 at 22 UK medical schools were analysed. The mean quantity of oncology lectures students reported receiving was 8.9 hours and the mean quantity of clinic/ward-based oncology teaching was 7.5 hours. Ninety (62.1%) of the 145 students who responded to the relevant question reported that they had received dedicated teaching in oncology. Students who had received dedicated oncology teaching reported a statistically significantly higher mean quality 6.1 (95% confidence interval 5.6-6.5) versus 5.0 (95% confidence interval 4.3-5.5; P = 0.003) and quantity 5.2 (95% confidence interval 4.7-5.6) versus 4.3 (95% confidence interval 3.7-4.9; P = 0.03) of oncology teaching compared with those who had not received this. CONCLUSION Appropriate oncology education is essential for all medical students due to the high prevalence of cancer. All future doctors need the appropriate knowledge and communication skills to care for cancer patients. Our analysis provides quantitative evidence to support the value of specialist oncology teaching within the medical school curriculum in improving student-reported experience. National student-led revision days and events may widen interest in a future career in oncology and aid collaboration between oncology societies. It is important for the general undergraduate medical curriculum to integrate specialty content. An integrated curriculum should facilitate a holistic approach that spans prevention, screening, treatment and palliation rather than being split by subspeciality.
Collapse
Affiliation(s)
- S R Heritage
- School of Clinical Medicine, University of Cambridge, Cambridge, UK.
| | - K Lynch-Kelly
- GKT School of Medical Education, King's College London, London, UK
| | - J Kalvala
- School of Medicine, University of Nottingham, Nottingham, UK
| | - R Tulloch
- School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, UK
| | - A Devasar
- Edinburgh Medical School, The University of Edinburgh, Edinburgh, UK
| | - J Harewood
- School of Medical Education, Newcastle University, Newcastle, UK
| | - E Khoury
- School of Medicine, University of Liverpool, Liverpool, UK
| | - A Abdelwahed
- School of Medicine, Imperial College London, London, UK
| | - A Fung
- Norwich Medical School, University of East Anglia, Norwich, UK
| | - C M Bigogno
- Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK
| | - R Gray
- School of Medicine, University of Dundee, Dundee, UK
| | - S Keshwara
- Whiston Hospital, St Helens and Knowsley Teaching Hospitals NHS Trust, Prescot, UK
| | - P J S Joseph
- School of Medicine, University of Liverpool, Liverpool, UK
| | - P Selby
- University of Leeds, Leeds, UK; University of Lincoln, Lincoln, UK
| | | |
Collapse
|
8
|
Stubbs M, Hey J, Fung A, Maynard J, Parnell B, Sinha A. P.21 A multidisciplinary safety checklist to facilitate continuous fetal heart monitoring during labour epidural analgesia insertion. Int J Obstet Anesth 2022. [DOI: 10.1016/j.ijoa.2022.103317] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
9
|
Fung A, Soundappan D, Loewenstein D, Playford D, Strange G, Kozor R, Otton J, Ugander M. Prognostic Association Supports Indexing Size Measures in Echocardiography by Body Surface Area. Heart Lung Circ 2022. [DOI: 10.1016/j.hlc.2022.06.277] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
10
|
Soundappan D, Fung A, Loewenstein D, Playford D, Strange G, Kozor R, Otton J, Ugander M. Decreased Hydraulic Forces Incrementally Associate With Survival Beyond Conventional Measures of Diastolic Function. Heart Lung Circ 2022. [DOI: 10.1016/j.hlc.2022.06.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
|
11
|
Moore S, Agulnik J, Bebb G, Dawe D, Elegbede A, Fung A, Ho C, Liu G, Lok B, Snow S, Wheatley-Price P. P64.01 The Canadian Small Cell Lung Cancer Database (CASCaDe): A Multi-Institutional Real-World Evidence Collaboration. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.672] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
12
|
Lau S, Rabindranath M, Weiss J, Li J, Nirmalakumar S, Ruff H, Boerner S, Tong L, Tsao M, Pal P, Cabanero M, Hsu Y, Fung A, Sacher A, Shepherd F, Liu G, Bradbury P, Yasufuku K, Czarnecka-Kujawa K, Ko H, Leighl N, Schwock J. FP12.01 PD-L1 Assessment in Cytology is Comparable to Histology in Predicting Treatment Response to Checkpoint Inhibitors in NSCLC. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.241] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
13
|
Lau S, Perdrizet K, Giffoni M.M. Mata D, Fung A, Liu G, Bradbury P, Shepherd F, Sacher A, Sheffield B, Hwang D, Tsao M, Cheng S, Cheema P, Leighl N. P45.05 Sequencing of PD-1 Inhibitors and TKIs in Metastatic NSCLC with MET Exon 14 Skipping Mutation May Influence Survival. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.473] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
14
|
Fung A, Ward A, Patel K, Krkovic M. 1005 Antibiotic-Impregnated Calcium Sulfate Beads Are Not Effective in the Primary Prevention of Infection in Open Femur and Tibia Fractures. Br J Surg 2021. [DOI: 10.1093/bjs/znab134.596] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
Abstract
Introduction
Infection is a major complication of open fractures. Antibiotic-impregnated calcium sulfate (AICS) beads are widely used as an adjuvant to systemic antibiotics. Whilst their efficacy in the secondary prevention of infection is established, we present the first retrospective study evaluating AICS beads in the primary prevention of infection in open fractures.
Method
214 open femur and tibia fractures in 207 patients were reviewed over a seven-year period. 148 fractures received only systemic antibiotic prophylaxis. 66 fractures also received AICS beads. The occurrence of acute infection (wound infection and acute osteomyelitis) was recorded, as well as that of long-term complications (chronic osteomyelitis, non-union and death).
Results
Fractures that received AICS with systemic antibiotics had an overall acute infection rate of 42% (28/66), compared to 43% (63/148) in fractures that received only systemic antibiotics (p > 0.05). There was no significant difference in infection rate even when fractures were stratified by Gustilo-Anderson grade. There was also no significant difference in the rate of long-term complications.
Conclusions
Our results indicate that the adjuvant use of AICS beads is not effective for the primary prevention of acute infection or long-term complications in open leg fractures. Further research is needed to elucidate the factors influencing the outcomes of AICS use.
Collapse
Affiliation(s)
- A Fung
- University of Cambridge, Cambridge, United Kingdom
| | - A Ward
- University of Cambridge, Cambridge, United Kingdom
| | - K Patel
- Addenbrooke's Hospital, Cambridge, United Kingdom
| | - M Krkovic
- Addenbrooke's Hospital, Cambridge, United Kingdom
| |
Collapse
|
15
|
De Leoz MLA, Duewer DL, Fung A, Liu L, Yau HK, Potter O, Staples GO, Furuki K, Frenkel R, Hu Y, Sosic Z, Zhang P, Altmann F, Grunwald-Grube C, Shao C, Zaia J, Evers W, Pengelley S, Suckau D, Wiechmann A, Resemann A, Jabs W, Beck A, Froehlich JW, Huang C, Li Y, Liu Y, Sun S, Wang Y, Seo Y, An HJ, Reichardt NC, Ruiz JE, Archer-Hartmann S, Azadi P, Bell L, Lakos Z, An Y, Cipollo JF, Pucic-Bakovic M, Štambuk J, Lauc G, Li X, Wang PG, Bock A, Hennig R, Rapp E, Creskey M, Cyr TD, Nakano M, Sugiyama T, Leung PKA, Link-Lenczowski P, Jaworek J, Yang S, Zhang H, Kelly T, Klapoetke S, Cao R, Kim JY, Lee HK, Lee JY, Yoo JS, Kim SR, Suh SK, de Haan N, Falck D, Lageveen-Kammeijer GSM, Wuhrer M, Emery RJ, Kozak RP, Liew LP, Royle L, Urbanowicz PA, Packer NH, Song X, Everest-Dass A, Lattová E, Cajic S, Alagesan K, Kolarich D, Kasali T, Lindo V, Chen Y, Goswami K, Gau B, Amunugama R, Jones R, Stroop CJM, Kato K, Yagi H, Kondo S, Yuen CT, Harazono A, Shi X, Magnelli PE, Kasper BT, Mahal L, Harvey DJ, O'Flaherty R, Rudd PM, Saldova R, Hecht ES, Muddiman DC, Kang J, Bhoskar P, Menard D, Saati A, Merle C, Mast S, Tep S, Truong J, Nishikaze T, Sekiya S, Shafer A, Funaoka S, Toyoda M, de Vreugd P, Caron C, Pradhan P, Tan NC, Mechref Y, Patil S, Rohrer JS, Chakrabarti R, Dadke D, Lahori M, Zou C, Cairo C, Reiz B, Whittal RM, Lebrilla CB, Wu L, Guttman A, Szigeti M, Kremkow BG, Lee KH, Sihlbom C, Adamczyk B, Jin C, Karlsson NG, Örnros J, Larson G, Nilsson J, Meyer B, Wiegandt A, Komatsu E, Perreault H, Bodnar ED, Said N, Francois YN, Leize-Wagner E, Maier S, Zeck A, Heck AJR, Yang Y, Haselberg R, Yu YQ, Alley W, Leone JW, Yuan H, Stein SE. NIST Interlaboratory Study on Glycosylation Analysis of Monoclonal Antibodies: Comparison of Results from Diverse Analytical Methods. Mol Cell Proteomics 2020; 19:11-30. [PMID: 31591262 PMCID: PMC6944243 DOI: 10.1074/mcp.ra119.001677] [Citation(s) in RCA: 67] [Impact Index Per Article: 16.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2019] [Revised: 08/26/2019] [Indexed: 01/24/2023] Open
Abstract
Glycosylation is a topic of intense current interest in the development of biopharmaceuticals because it is related to drug safety and efficacy. This work describes results of an interlaboratory study on the glycosylation of the Primary Sample (PS) of NISTmAb, a monoclonal antibody reference material. Seventy-six laboratories from industry, university, research, government, and hospital sectors in Europe, North America, Asia, and Australia submitted a total of 103 reports on glycan distributions. The principal objective of this study was to report and compare results for the full range of analytical methods presently used in the glycosylation analysis of mAbs. Therefore, participation was unrestricted, with laboratories choosing their own measurement techniques. Protein glycosylation was determined in various ways, including at the level of intact mAb, protein fragments, glycopeptides, or released glycans, using a wide variety of methods for derivatization, separation, identification, and quantification. Consequently, the diversity of results was enormous, with the number of glycan compositions identified by each laboratory ranging from 4 to 48. In total, one hundred sixteen glycan compositions were reported, of which 57 compositions could be assigned consensus abundance values. These consensus medians provide community-derived values for NISTmAb PS. Agreement with the consensus medians did not depend on the specific method or laboratory type. The study provides a view of the current state-of-the-art for biologic glycosylation measurement and suggests a clear need for harmonization of glycosylation analysis methods.
Collapse
Affiliation(s)
- Maria Lorna A De Leoz
- Mass Spectrometry Data Center, Biomolecular Measurement Division, Material Measurement Laboratory, National Institute of Standards and Technology, 100 Bureau Drive Gaithersburg, Maryland 20899.
| | - David L Duewer
- Chemical Sciences Division, Material Measurement Laboratory, National Institute of Standards and Technology, 100 Bureau Drive Gaithersburg, Maryland 20899
| | - Adam Fung
- Analytical Development, Agensys, Inc., 1800 Steward Street Santa Monica, California 90404
| | - Lily Liu
- Analytical Development, Agensys, Inc., 1800 Steward Street Santa Monica, California 90404
| | - Hoi Kei Yau
- Analytical Development, Agensys, Inc., 1800 Steward Street Santa Monica, California 90404
| | - Oscar Potter
- Agilent Technologies, Inc., 5301 Stevens Creek Blvd Santa Clara, California 95051
| | - Gregory O Staples
- Agilent Technologies, Inc., 5301 Stevens Creek Blvd Santa Clara, California 95051
| | - Kenichiro Furuki
- Astellas Pharma, 5-2-3 Tokodai, Tsukiba, Ibaraki, 300-2698, Japan
| | - Ruth Frenkel
- Analytical Development, Biogen, 14 Cambridge Center Cambridge, Massachusetts 02142
| | - Yunli Hu
- Analytical Development, Biogen, 14 Cambridge Center Cambridge, Massachusetts 02142
| | - Zoran Sosic
- Analytical Development, Biogen, 14 Cambridge Center Cambridge, Massachusetts 02142
| | - Peiqing Zhang
- Bioprocessing Technology Institute, 20 Biopolis Way, Level 3 Singapore 138668
| | - Friedrich Altmann
- Department of Chemistry, University of Natural Resources and Life Science, Vienna (BOKU), Muthgasse 18 1190 Wien, Austria
| | - Clemens Grunwald-Grube
- Department of Chemistry, University of Natural Resources and Life Science, Vienna (BOKU), Muthgasse 18 1190 Wien, Austria
| | - Chun Shao
- Center for Biomedical Mass Spectrometry, Boston University School of Medicine, 670 Albany Street Boston, Massachusetts 02118
| | - Joseph Zaia
- Center for Biomedical Mass Spectrometry, Boston University School of Medicine, 670 Albany Street Boston, Massachusetts 02118
| | - Waltraud Evers
- Bruker Daltonik GmbH, Fahrenheitstr. 4, 28359 Bremen, Germany
| | | | - Detlev Suckau
- Bruker Daltonik GmbH, Fahrenheitstr. 4, 28359 Bremen, Germany
| | - Anja Wiechmann
- Bruker Daltonik GmbH, Fahrenheitstr. 4, 28359 Bremen, Germany
| | - Anja Resemann
- Bruker Daltonik GmbH, Fahrenheitstr. 4, 28359 Bremen, Germany
| | - Wolfgang Jabs
- Bruker Daltonik GmbH, Fahrenheitstr. 4, 28359 Bremen, Germany; Department of Life Sciences & Technology, Beuth Hochschule für Technik Berlin, Seestraβe 64, 13347 Berlin, Germany
| | - Alain Beck
- Centre d'Immunologie Pierre Fabre, 5 Avenue Napoléon III, BP 60497, 74164 St Julien-en-Genevois, France
| | - John W Froehlich
- Department of Urology, Boston Children's Hospital, 300 Longwood Avenue Boston Massachusetts 02115
| | - Chuncui Huang
- Institute of Biophysics, Chinese Academy of Sciences, 15 Da Tun Road, Chaoyang District, Beijing 100101 China
| | - Yan Li
- Institute of Biophysics, Chinese Academy of Sciences, 15 Da Tun Road, Chaoyang District, Beijing 100101 China
| | - Yaming Liu
- Institute of Biophysics, Chinese Academy of Sciences, 15 Da Tun Road, Chaoyang District, Beijing 100101 China
| | - Shiwei Sun
- Key Lab of Intelligent Information Processing, Institute of Computing Technology, Chinese Academy of Sciences, 15 Da Tun Road, Chaoyang District, Beijing 100101 China
| | - Yaojun Wang
- Key Lab of Intelligent Information Processing, Institute of Computing Technology, Chinese Academy of Sciences, 15 Da Tun Road, Chaoyang District, Beijing 100101 China
| | - Youngsuk Seo
- Graduate School of Analytical Science and Technology, Chungnam National University, Gung-dong 220, Yuseong-Gu, Daejeon 305-764, Korea (South)
| | - Hyun Joo An
- Graduate School of Analytical Science and Technology, Chungnam National University, Gung-dong 220, Yuseong-Gu, Daejeon 305-764, Korea (South)
| | | | | | - Stephanie Archer-Hartmann
- Analytical Services, Complex Carbohydrate Research Center, University of Georgia, 315 Riverbend Road Athens, Georgia 30602
| | - Parastoo Azadi
- Analytical Services, Complex Carbohydrate Research Center, University of Georgia, 315 Riverbend Road Athens, Georgia 30602
| | - Len Bell
- BioCMC Solutions (Large Molecules), Covance Laboratories Limited, Otley Road, Harrogate, North Yorks HG3 1PY, United Kingdom
| | - Zsuzsanna Lakos
- Biochemistry Method Development & Validation, Eurofins Lancaster Laboratories, Inc., 2425 New Holland Pike Lancaster, Pennsylvania 17601
| | - Yanming An
- Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, Maryland 20993
| | - John F Cipollo
- Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, Maryland 20993
| | - Maja Pucic-Bakovic
- Glycoscience Research Laboratory, Genos, Borongajska cesta 83h, 10 000 Zagreb, Croatia
| | - Jerko Štambuk
- Glycoscience Research Laboratory, Genos, Borongajska cesta 83h, 10 000 Zagreb, Croatia
| | - Gordan Lauc
- Glycoscience Research Laboratory, Genos, Borongajska cesta 83h, 10 000 Zagreb, Croatia; Faculty of Pharmacy and Biochemistry, University of Zagreb, A. Kovačića 1, 10 000 Zagreb, Croatia
| | - Xu Li
- Department of Chemistry, Georgia State University, 100 Piedmont Avenue, Atlanta, Georgia 30303
| | - Peng George Wang
- Department of Chemistry, Georgia State University, 100 Piedmont Avenue, Atlanta, Georgia 30303
| | - Andreas Bock
- glyXera GmbH, Brenneckestrasse 20 * ZENIT / 39120 Magdeburg, Germany
| | - René Hennig
- glyXera GmbH, Brenneckestrasse 20 * ZENIT / 39120 Magdeburg, Germany
| | - Erdmann Rapp
- glyXera GmbH, Brenneckestrasse 20 * ZENIT / 39120 Magdeburg, Germany; AstraZeneca, Granta Park, Cambridgeshire, CB21 6GH United Kingdom
| | - Marybeth Creskey
- Health Products and Foods Branch, Health Canada, AL 2201E, 251 Sir Frederick Banting Driveway, Ottawa, Ontario, K1A 0K9 Canada
| | - Terry D Cyr
- Health Products and Foods Branch, Health Canada, AL 2201E, 251 Sir Frederick Banting Driveway, Ottawa, Ontario, K1A 0K9 Canada
| | - Miyako Nakano
- Graduate School of Advanced Sciences of Matter, Hiroshima University, 1-3-1 Kagamiyama Higashi-Hiroshima 739-8530 Japan
| | - Taiki Sugiyama
- Graduate School of Advanced Sciences of Matter, Hiroshima University, 1-3-1 Kagamiyama Higashi-Hiroshima 739-8530 Japan
| | | | - Paweł Link-Lenczowski
- Department of Medical Physiology, Jagiellonian University Medical College, ul. Michalowskiego 12, 31-126 Krakow, Poland
| | - Jolanta Jaworek
- Department of Medical Physiology, Jagiellonian University Medical College, ul. Michalowskiego 12, 31-126 Krakow, Poland
| | - Shuang Yang
- Department of Pathology, Johns Hopkins University, 400 N. Broadway Street Baltimore, Maryland 21287
| | - Hui Zhang
- Department of Pathology, Johns Hopkins University, 400 N. Broadway Street Baltimore, Maryland 21287
| | - Tim Kelly
- Mass Spec Core Facility, KBI Biopharma, 1101 Hamlin Road Durham, North Carolina 27704
| | - Song Klapoetke
- Mass Spec Core Facility, KBI Biopharma, 1101 Hamlin Road Durham, North Carolina 27704
| | - Rui Cao
- Mass Spec Core Facility, KBI Biopharma, 1101 Hamlin Road Durham, North Carolina 27704
| | - Jin Young Kim
- Division of Mass Spectrometry, Korea Basic Science Institute, 162 YeonGuDanji-Ro, Ochang-eup, Cheongwon-gu, Cheongju Chungbuk, 363-883 Korea (South)
| | - Hyun Kyoung Lee
- Division of Mass Spectrometry, Korea Basic Science Institute, 162 YeonGuDanji-Ro, Ochang-eup, Cheongwon-gu, Cheongju Chungbuk, 363-883 Korea (South)
| | - Ju Yeon Lee
- Division of Mass Spectrometry, Korea Basic Science Institute, 162 YeonGuDanji-Ro, Ochang-eup, Cheongwon-gu, Cheongju Chungbuk, 363-883 Korea (South)
| | - Jong Shin Yoo
- Division of Mass Spectrometry, Korea Basic Science Institute, 162 YeonGuDanji-Ro, Ochang-eup, Cheongwon-gu, Cheongju Chungbuk, 363-883 Korea (South)
| | - Sa-Rang Kim
- Advanced Therapy Products Research Division, Korea National Institute of Food and Drug Safety, 187 Osongsaengmyeong 2-ro Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do, 363-700, Korea (South)
| | - Soo-Kyung Suh
- Advanced Therapy Products Research Division, Korea National Institute of Food and Drug Safety, 187 Osongsaengmyeong 2-ro Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do, 363-700, Korea (South)
| | - Noortje de Haan
- Center for Proteomics and Metabolomics, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands
| | - David Falck
- Center for Proteomics and Metabolomics, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands
| | | | - Manfred Wuhrer
- Center for Proteomics and Metabolomics, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands
| | - Robert J Emery
- Ludger Limited, Culham Science Centre, Abingdon, Oxfordshire, OX14 3EB, United Kingdom
| | - Radoslaw P Kozak
- Ludger Limited, Culham Science Centre, Abingdon, Oxfordshire, OX14 3EB, United Kingdom
| | - Li Phing Liew
- Ludger Limited, Culham Science Centre, Abingdon, Oxfordshire, OX14 3EB, United Kingdom
| | - Louise Royle
- Ludger Limited, Culham Science Centre, Abingdon, Oxfordshire, OX14 3EB, United Kingdom
| | - Paulina A Urbanowicz
- Ludger Limited, Culham Science Centre, Abingdon, Oxfordshire, OX14 3EB, United Kingdom
| | - Nicolle H Packer
- Biomolecular Discovery and Design Research Centre and ARC Centre of Excellence for Nanoscale BioPhotonics (CNBP), Macquarie University, North Ryde, Australia
| | - Xiaomin Song
- Biomolecular Discovery and Design Research Centre and ARC Centre of Excellence for Nanoscale BioPhotonics (CNBP), Macquarie University, North Ryde, Australia
| | - Arun Everest-Dass
- Biomolecular Discovery and Design Research Centre and ARC Centre of Excellence for Nanoscale BioPhotonics (CNBP), Macquarie University, North Ryde, Australia
| | - Erika Lattová
- Proteomics, Central European Institute for Technology, Masaryk University, Kamenice 5, A26, 625 00 BRNO, Czech Republic
| | - Samanta Cajic
- Max Planck Institute for Dynamics of Complex Technical Systems, Sandtorstrasse 1, 39106 Magdeburg, Germany
| | - Kathirvel Alagesan
- Department of Biomolecular Sciences, Max Planck Institute of Colloids and Interfaces, 14424 Potsdam, Germany
| | - Daniel Kolarich
- Department of Biomolecular Sciences, Max Planck Institute of Colloids and Interfaces, 14424 Potsdam, Germany
| | - Toyin Kasali
- AstraZeneca, Granta Park, Cambridgeshire, CB21 6GH United Kingdom
| | - Viv Lindo
- AstraZeneca, Granta Park, Cambridgeshire, CB21 6GH United Kingdom
| | - Yuetian Chen
- Merck, 2015 Galloping Hill Rd, Kenilworth, New Jersey 07033
| | - Kudrat Goswami
- Merck, 2015 Galloping Hill Rd, Kenilworth, New Jersey 07033
| | - Brian Gau
- Analytical R&D, MilliporeSigma, 2909 Laclede Ave. St. Louis, Missouri 63103
| | - Ravi Amunugama
- MS Bioworks, LLC, 3950 Varsity Drive Ann Arbor, Michigan 48108
| | - Richard Jones
- MS Bioworks, LLC, 3950 Varsity Drive Ann Arbor, Michigan 48108
| | | | - Koichi Kato
- Exploratory Research Center on Life and Living Systems (ExCELLS), National Institutes of Natural Sciences, 5-1 Higashiyama, Myodaiji, Okazaki 444-8787 Japan; Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-dori, Mizuhoku, Nagoya 467-8603 Japan
| | - Hirokazu Yagi
- Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-dori, Mizuhoku, Nagoya 467-8603 Japan
| | - Sachiko Kondo
- Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-dori, Mizuhoku, Nagoya 467-8603 Japan; Medical & Biological Laboratories Co., Ltd, 2-22-8 Chikusa, Chikusa-ku, Nagoya 464-0858 Japan
| | - C T Yuen
- National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG United Kingdom
| | - Akira Harazono
- Division of Biological Chemistry & Biologicals, National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501 Japan
| | - Xiaofeng Shi
- New England Biolabs, Inc., 240 County Road, Ipswich, Massachusetts 01938
| | - Paula E Magnelli
- New England Biolabs, Inc., 240 County Road, Ipswich, Massachusetts 01938
| | - Brian T Kasper
- New York University, 100 Washington Square East New York City, New York 10003
| | - Lara Mahal
- New York University, 100 Washington Square East New York City, New York 10003
| | - David J Harvey
- Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Roosevelt Drive, Oxford, OX3 7FZ, United Kingdom
| | - Roisin O'Flaherty
- GlycoScience Group, The National Institute for Bioprocessing Research and Training, Fosters Avenue, Mount Merrion, Blackrock, Co. Dublin, Ireland
| | - Pauline M Rudd
- GlycoScience Group, The National Institute for Bioprocessing Research and Training, Fosters Avenue, Mount Merrion, Blackrock, Co. Dublin, Ireland
| | - Radka Saldova
- GlycoScience Group, The National Institute for Bioprocessing Research and Training, Fosters Avenue, Mount Merrion, Blackrock, Co. Dublin, Ireland
| | - Elizabeth S Hecht
- Department of Chemistry, North Carolina State University, 2620 Yarborough Drive Raleigh, North Carolina 27695
| | - David C Muddiman
- Department of Chemistry, North Carolina State University, 2620 Yarborough Drive Raleigh, North Carolina 27695
| | - Jichao Kang
- Pantheon, 201 College Road East Princeton, New Jersey 08540
| | | | | | - Andrew Saati
- Pfizer Inc., 1 Burtt Road Andover, Massachusetts 01810
| | - Christine Merle
- Proteodynamics, ZI La Varenne 20-22 rue Henri et Gilberte Goudier 63200 RIOM, France
| | - Steven Mast
- ProZyme, Inc., 3832 Bay Center Place Hayward, California 94545
| | - Sam Tep
- ProZyme, Inc., 3832 Bay Center Place Hayward, California 94545
| | - Jennie Truong
- ProZyme, Inc., 3832 Bay Center Place Hayward, California 94545
| | - Takashi Nishikaze
- Koichi Tanaka Mass Spectrometry Research Laboratory, Shimadzu Corporation, 1 Nishinokyo Kuwabara-cho Nakagyo-ku, Kyoto, 604 8511 Japan
| | - Sadanori Sekiya
- Koichi Tanaka Mass Spectrometry Research Laboratory, Shimadzu Corporation, 1 Nishinokyo Kuwabara-cho Nakagyo-ku, Kyoto, 604 8511 Japan
| | - Aaron Shafer
- Children's GMP LLC, St. Jude Children's Research Hospital, 262 Danny Thomas Place Memphis, Tennessee 38105
| | - Sohei Funaoka
- Sumitomo Bakelite Co., Ltd., 1-5 Muromati 1-Chome, Nishiku, Kobe, 651-2241 Japan
| | - Masaaki Toyoda
- Sumitomo Bakelite Co., Ltd., 1-5 Muromati 1-Chome, Nishiku, Kobe, 651-2241 Japan
| | - Peter de Vreugd
- Synthon Biopharmaceuticals, Microweg 22 P.O. Box 7071, 6503 GN Nijmegen, The Netherlands
| | - Cassie Caron
- Takeda Pharmaceuticals International Co., 40 Landsdowne Street Cambridge, Massachusetts 02139
| | - Pralima Pradhan
- Takeda Pharmaceuticals International Co., 40 Landsdowne Street Cambridge, Massachusetts 02139
| | - Niclas Chiang Tan
- Takeda Pharmaceuticals International Co., 40 Landsdowne Street Cambridge, Massachusetts 02139
| | - Yehia Mechref
- Department of Chemistry and Biochemistry, Texas Tech University, 2500 Broadway, Lubbock, Texas 79409
| | - Sachin Patil
- Thermo Fisher Scientific, 1214 Oakmead Parkway Sunnyvale, California 94085
| | - Jeffrey S Rohrer
- Thermo Fisher Scientific, 1214 Oakmead Parkway Sunnyvale, California 94085
| | - Ranjan Chakrabarti
- United States Pharmacopeia India Pvt. Ltd. IKP Knowledge Park, Genome Valley, Shamirpet, Turkapally Village, Medchal District, Hyderabad 500 101 Telangana, India
| | - Disha Dadke
- United States Pharmacopeia India Pvt. Ltd. IKP Knowledge Park, Genome Valley, Shamirpet, Turkapally Village, Medchal District, Hyderabad 500 101 Telangana, India
| | - Mohammedazam Lahori
- United States Pharmacopeia India Pvt. Ltd. IKP Knowledge Park, Genome Valley, Shamirpet, Turkapally Village, Medchal District, Hyderabad 500 101 Telangana, India
| | - Chunxia Zou
- Alberta Glycomics Centre, University of Alberta, Edmonton, Alberta T6G 2G2 Canada; Department of Chemistry, University of Alberta, Edmonton, Alberta T6G 2G2 Canada
| | - Christopher Cairo
- Alberta Glycomics Centre, University of Alberta, Edmonton, Alberta T6G 2G2 Canada; Department of Chemistry, University of Alberta, Edmonton, Alberta T6G 2G2 Canada
| | - Béla Reiz
- Department of Chemistry, University of Alberta, Edmonton, Alberta T6G 2G2 Canada
| | - Randy M Whittal
- Department of Chemistry, University of Alberta, Edmonton, Alberta T6G 2G2 Canada
| | - Carlito B Lebrilla
- Department of Chemistry, University of California, One Shields Ave, Davis, California 95616
| | - Lauren Wu
- Department of Chemistry, University of California, One Shields Ave, Davis, California 95616
| | - Andras Guttman
- Horváth Csaba Memorial Laboratory for Bioseparation Sciences, Research Center for Molecular Medicine, Doctoral School of Molecular Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Egyetem ter 1, Hungary
| | - Marton Szigeti
- Horváth Csaba Memorial Laboratory for Bioseparation Sciences, Research Center for Molecular Medicine, Doctoral School of Molecular Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Egyetem ter 1, Hungary; Translational Glycomics Research Group, Research Institute of Biomolecular and Chemical Engineering, University of Pannonia, Veszprem, Egyetem ut 10, Hungary
| | - Benjamin G Kremkow
- Delaware Biotechnology Institute, University of Delaware, 15 Innovation Way Newark, Delaware 19711
| | - Kelvin H Lee
- Delaware Biotechnology Institute, University of Delaware, 15 Innovation Way Newark, Delaware 19711
| | - Carina Sihlbom
- Proteomics Core Facility, University of Gothenburg, Medicinaregatan 1G SE 41390 Gothenburg, Sweden
| | - Barbara Adamczyk
- Department of Medical Biochemistry and Cell Biology, University of Gothenburg, Institute of Biomedicine, Sahlgrenska Academy, Medicinaregatan 9A, Box 440, 405 30, Gothenburg, Sweden
| | - Chunsheng Jin
- Department of Medical Biochemistry and Cell Biology, University of Gothenburg, Institute of Biomedicine, Sahlgrenska Academy, Medicinaregatan 9A, Box 440, 405 30, Gothenburg, Sweden
| | - Niclas G Karlsson
- Department of Medical Biochemistry and Cell Biology, University of Gothenburg, Institute of Biomedicine, Sahlgrenska Academy, Medicinaregatan 9A, Box 440, 405 30, Gothenburg, Sweden
| | - Jessica Örnros
- Department of Medical Biochemistry and Cell Biology, University of Gothenburg, Institute of Biomedicine, Sahlgrenska Academy, Medicinaregatan 9A, Box 440, 405 30, Gothenburg, Sweden
| | - Göran Larson
- Department of Clinical Chemistry and Transfusion Medicine, Sahlgrenska Academy at the University of Gothenburg, Bruna Straket 16, 41345 Gothenburg, Sweden
| | - Jonas Nilsson
- Department of Clinical Chemistry and Transfusion Medicine, Sahlgrenska Academy at the University of Gothenburg, Bruna Straket 16, 41345 Gothenburg, Sweden
| | - Bernd Meyer
- Department of Chemistry, University of Hamburg, Martin Luther King Pl. 6 20146 Hamburg, Germany
| | - Alena Wiegandt
- Department of Chemistry, University of Hamburg, Martin Luther King Pl. 6 20146 Hamburg, Germany
| | - Emy Komatsu
- Department of Chemistry, University of Manitoba, 144 Dysart Road, Winnipeg, Manitoba, Canada R3T 2N2
| | - Helene Perreault
- Department of Chemistry, University of Manitoba, 144 Dysart Road, Winnipeg, Manitoba, Canada R3T 2N2
| | - Edward D Bodnar
- Department of Chemistry, University of Manitoba, 144 Dysart Road, Winnipeg, Manitoba, Canada R3T 2N2; Agilent Technologies, Inc., 5301 Stevens Creek Blvd Santa Clara, California 95051
| | - Nassur Said
- Laboratory of Mass Spectrometry of Interactions and Systems, University of Strasbourg, UMR Unistra-CNRS 7140, France
| | - Yannis-Nicolas Francois
- Laboratory of Mass Spectrometry of Interactions and Systems, University of Strasbourg, UMR Unistra-CNRS 7140, France
| | - Emmanuelle Leize-Wagner
- Laboratory of Mass Spectrometry of Interactions and Systems, University of Strasbourg, UMR Unistra-CNRS 7140, France
| | - Sandra Maier
- Natural and Medical Sciences Institute, University of Tübingen, Markwiesenstraβe 55, 72770 Reutlingen, Germany
| | - Anne Zeck
- Natural and Medical Sciences Institute, University of Tübingen, Markwiesenstraβe 55, 72770 Reutlingen, Germany
| | - Albert J R Heck
- Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Padualaan 8, 3584 CH Utrecht, The Netherlands
| | - Yang Yang
- Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Padualaan 8, 3584 CH Utrecht, The Netherlands
| | - Rob Haselberg
- Division of Bioanalytical Chemistry, Amsterdam Institute for Molecules, Medicines and Systems, Vrije Universiteit Amsterdam, de Boelelaan 1085, 1081 HV Amsterdam, The Netherlands
| | - Ying Qing Yu
- Department of Chemistry, Waters Corporation, 34 Maple Street Milford, Massachusetts 01757
| | - William Alley
- Department of Chemistry, Waters Corporation, 34 Maple Street Milford, Massachusetts 01757
| | | | - Hua Yuan
- Zoetis, 333 Portage St. Kalamazoo, Michigan 49007
| | - Stephen E Stein
- Mass Spectrometry Data Center, Biomolecular Measurement Division, Material Measurement Laboratory, National Institute of Standards and Technology, 100 Bureau Drive Gaithersburg, Maryland 20899
| |
Collapse
|
16
|
Moulson N, Fung A, Balthazaar S, Girgis H, Van Woudenberg N, Luong C, Gin K, Jue J, Tsang M, Nair P, Abolmaesumi P, Tsang T. ARTIFICIAL INTELLIGENCE ASSESSMENT OF LEFT VENTRICULAR VOLUMES AND FUNCTION ON POCUS IMAGING. Can J Cardiol 2019. [DOI: 10.1016/j.cjca.2019.07.059] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
|
17
|
Fung A, Moulson N, Balthazaar S, Girgis H, Van Woudenberg N, Abolmaesumi P, Luong C, Gin K, Jue J, Tsang M, Nair P, Tsang T. CAN ARTIFICIAL INTELLIGENCE ASSESS IMAGE QUALITY IN POINT-OF-CARE ULTRASOUND? Can J Cardiol 2019. [DOI: 10.1016/j.cjca.2019.07.566] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
18
|
Fitzsimons R, Jones P, Fung A, Jones T. P.39Genetic and disease analysis of FSHD-linked 4q35 region in female Coats Disease patients. Neuromuscul Disord 2019. [DOI: 10.1016/j.nmd.2019.06.068] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
19
|
Lo YJ, Fung A, Lai YL, Lau CH, Tong KL. Gastric Volvulus ‐ Two Ends of the Spectrum. Surg Pract 2018. [DOI: 10.1111/1744-1633.12354] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Affiliation(s)
- YJ Lo
- Surgical DepartmentQueen Elizabeth Hospital Hong Kong
| | - A Fung
- Surgical DepartmentQueen Elizabeth Hospital Hong Kong
| | - YL Lai
- Surgical DepartmentQueen Elizabeth Hospital Hong Kong
| | - CH Lau
- Surgical DepartmentQueen Elizabeth Hospital Hong Kong
| | - KL Tong
- Surgical DepartmentQueen Elizabeth Hospital Hong Kong
| |
Collapse
|
20
|
Lee H, Stacey A, Klesert T, Wells C, Skalet A, Bloch C, Fung A, Bowen S, Wong T, Shibata D, Halasz L, Rengan R. A Contour-Based Approach for Predicting Corneal Toxicity in Patients with Uveal Melanoma Treated with Proton Therapy. Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2018.07.939] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
21
|
Abstract
Antibody-drug conjugates (ADCs) that are formed using thiol-maleimide chemistry are commonly produced by reactions that occur at or above neutral pHs. Alkaline environments can promote disulfide bond scrambling, and may result in the reconfiguration of interchain disulfide bonds in IgG antibodies, particularly in the IgG2 and IgG4 subclasses. IgG2-A and IgG2-B antibodies generated under basic conditions yielded ADCs with comparable average drug-to-antibody ratios and conjugate distributions. In contrast, the antibody disulfide configuration affected the distribution of ADCs generated under acidic conditions. The similarities of the ADCs derived from alkaline reactions were attributed to the scrambling of interchain disulfide bonds during the partial reduction step, where conversion of the IgG2-A isoform to the IgG2-B isoform was favored.
Collapse
Affiliation(s)
- Lily Pei-Yao Liu-Shin
- a Analytical and Formulation Development , Agensys, Inc., an affiliate of Astellas, Inc , Santa Monica , CA , USA.,b Department of Biochemistry and Molecular Biology , University of Miami Miller School of Medicine , Miami , FL , USA
| | - Adam Fung
- a Analytical and Formulation Development , Agensys, Inc., an affiliate of Astellas, Inc , Santa Monica , CA , USA
| | - Arun Malhotra
- b Department of Biochemistry and Molecular Biology , University of Miami Miller School of Medicine , Miami , FL , USA
| | - Gayathri Ratnaswamy
- a Analytical and Formulation Development , Agensys, Inc., an affiliate of Astellas, Inc , Santa Monica , CA , USA
| |
Collapse
|
22
|
Resemann A, Liu-Shin L, Tremintin G, Malhotra A, Fung A, Wang F, Ratnaswamy G, Suckau D. Rapid, automated characterization of disulfide bond scrambling and IgG2 isoform determination. MAbs 2018; 10:1200-1213. [PMID: 30277844 PMCID: PMC6284591 DOI: 10.1080/19420862.2018.1512328] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
Abstract
Human antibodies of the IgG2 subclass exhibit complex inter-chain disulfide bonding patterns that result in three structures, namely A, A/B, and B. In therapeutic applications, the distribution of disulfide isoforms is a critical product quality attribute because each configuration affects higher order structure, stability, isoelectric point, and antigen binding. The current standard for quantification of IgG2 disulfide isoform distribution is based on chromatographic or electrophoretic techniques that require additional characterization using mass spectrometry (MS)-based methods to confirm disulfide linkages. Detailed characterization of the IgG2 disulfide linkages often involve MS/MS approaches that include electrospray ionization or electron-transfer dissociation, and method optimization is often cumbersome due to the large size and heterogeneity of the disulfide-bonded peptides. As reported here, we developed a rapid LC-MALDI-TOF/TOF workflow that can both identify the IgG2 disulfide linkages and provide a semi-quantitative assessment of the distribution of the disulfide isoforms. We established signature disulfide-bonded IgG2 hinge peptides that correspond to the A, A/B, and B disulfide isoforms and can be applied to the fast classification of IgG2 isoforms in heterogeneous mixtures.
Collapse
Affiliation(s)
- Anja Resemann
- a BioPharma Solutions R&D , BALS, Bruker Daltonik , Bremen , Germany
| | - Lily Liu-Shin
- b Analytical and Formulation Development, Agensys, Inc., an affiliate of Astellas , Santa Monica , CA , USA.,c Department of Biochemistry and Molecular Biology , University of Miami Miller School of Medicine , Miami , FL , USA
| | | | - Arun Malhotra
- c Department of Biochemistry and Molecular Biology , University of Miami Miller School of Medicine , Miami , FL , USA
| | - Adam Fung
- b Analytical and Formulation Development, Agensys, Inc., an affiliate of Astellas , Santa Monica , CA , USA
| | - Fang Wang
- b Analytical and Formulation Development, Agensys, Inc., an affiliate of Astellas , Santa Monica , CA , USA
| | - Gayathri Ratnaswamy
- b Analytical and Formulation Development, Agensys, Inc., an affiliate of Astellas , Santa Monica , CA , USA
| | - Detlev Suckau
- a BioPharma Solutions R&D , BALS, Bruker Daltonik , Bremen , Germany
| |
Collapse
|
23
|
Fung A, Kopciuk K, Dean M, D'Silva A, Otsuka S, Klimowicz A, Hao D, Morris D, Bebb G. P3.03-21 CXCR4 Overexpression is Associated with Poor Survival Outcome After Recurrence in Early Stage Non-Small Cell Lung Cancer Patients. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1698] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
24
|
Pefanis A, Williams DS, Skrzypek H, Fung A, Paizis K. A case of ANCA-associated vasculitis presenting de novo in pregnancy, successfully treated with rituximab. Obstet Med 2018; 13:41-44. [PMID: 32284732 DOI: 10.1177/1753495x18780853] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2018] [Accepted: 04/26/2018] [Indexed: 12/16/2022] Open
Abstract
Antineutrophil cytoplasm antibody (ANCA)-associated vasculitides are rare small vessel vasculitides of unknown cause. The pathogenic role of MPO-ANCA in the vasculitides has been supported using various animal models, with B-cells playing a role in the disease pathogenesis. Pregnancy in the presence of an autoimmune disease such as vasculitis is often associated with significant morbidity. Little is known about the outcomes when women present with de novo vasculitis during pregnancy, and the appropriate management of such presentations is unclear. We describe a case of a 33-year-old female presenting in her second pregnancy with new onset ANCA vasculitis at 12 weeks' gestation. She was successfully treated with prednisolone and rituximab, and delivered a healthy 2.8 kg boy at 36 weeks' gestation with no clinical manifestations of vasculitis or neutropenia in the neonate.
Collapse
Affiliation(s)
- A Pefanis
- Department of Nephrology, Austin Health, Melbourne, Australia
| | - D S Williams
- Department of Nephrology, Austin Health, Melbourne, Australia
| | - H Skrzypek
- Department of Obstetric, Medicine, Mercy Health, Melbourne, Australia
| | - A Fung
- Department of Obstetric, Medicine, Mercy Health, Melbourne, Australia
| | - K Paizis
- Department of Nephrology, Austin Health, Melbourne, Australia.,Department of Obstetric, Medicine, Mercy Health, Melbourne, Australia
| |
Collapse
|
25
|
Abstract
Cysteine-linked antibody-drug conjugates (ADCs) produced from IgG2 monoclonal antibodies (mAbs) are more heterogeneous than ADCs generated from IgG1 mAbs, as IgG2 ADCs are composed of a wider distribution of molecules, typically containing 0 – 12 drug-linkers per antibody. The three disulfide isoforms (A, A/B, and B) of IgG2 antibodies confer differences in solvent accessibilities of the interchain disulfides and contribute to the structural heterogeneity of cysteine-linked ADCs. ADCs derived from either IgG2-A or IgG2-B mAbs were compared to better understand the role of disulfide isoforms on attachment sites and distribution of conjugated species. Our characterization of these ADCs demonstrated that the disulfide configuration affects the kinetics of disulfide bond reduction, but has minimal effect on the primary sites of reduction. The IgG2-A mAbs yielded ADCs with higher drug-to-antibody ratios (DARs) due to the easier reduction of its interchain disulfides. However, hinge-region cysteines were the primary conjugation sites for both IgG2-A and IgG2-B mAbs.
Collapse
Affiliation(s)
- Lily Liu-Shin
- a Analytical and Formulation Development, Agensys, Inc., an affiliate of Astellas, Inc. , Santa Monica , CA.,b Department of Biochemistry and Molecular Biology , University of Miami Miller School of Medicine , Miami , FL
| | - Adam Fung
- a Analytical and Formulation Development, Agensys, Inc., an affiliate of Astellas, Inc. , Santa Monica , CA
| | - Arun Malhotra
- b Department of Biochemistry and Molecular Biology , University of Miami Miller School of Medicine , Miami , FL
| | - Gayathri Ratnaswamy
- a Analytical and Formulation Development, Agensys, Inc., an affiliate of Astellas, Inc. , Santa Monica , CA
| |
Collapse
|
26
|
Daien V, Nguyen V, Essex RW, Morlet N, Barthelmes D, Gillies MC, Gillies M, Hunt A, Essex R, Dayajeewa C, Hunyor A, Fraser-Bell S, Younan C, Fung A, Guymer R, Louis D, Arnold J, Chan D, Cass H, Harper A, O’Day J, Daniell M, Field A, Chow L, Barthelmes D, Cohn A, Young S, Lal S, Ferrier R, Barnes R, Thompson A, Vincent A, Manning L, Lake S, Phillips R, Perks M, Chen J, Landers J, Niladri, Banerjee G, Swamy B, Windle P, Dunlop A, Tang K, McLean I, Amini A, Hunt A, Clark G, McAllister I, Chen F, Squirrell D, Ng C, Hinchcliffe P, Barry R, Ah-Chan J, Steiner H, Morgan M, Thompson C, Game J, Murray N. Incidence and Outcomes of Infectious and Noninfectious Endophthalmitis after Intravitreal Injections for Age-Related Macular Degeneration. Ophthalmology 2018; 125:66-74. [DOI: 10.1016/j.ophtha.2017.07.005] [Citation(s) in RCA: 45] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2017] [Revised: 06/19/2017] [Accepted: 07/06/2017] [Indexed: 10/19/2022] Open
|
27
|
Fung A, D'Silva A, Li H, Otsuka S, Bebb D. P2.01-026 Distribution of Metastatic Disease in Survival Outliers with Stage IV Non-Small Cell Lung Cancer. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.1128] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
28
|
Miles D, Im YH, Fung A, Yoo B, Knott A, Heeson S, Beattie MS, Swain SM. Effect of docetaxel duration on clinical outcomes: exploratory analysis of CLEOPATRA, a phase III randomized controlled trial. Ann Oncol 2017; 28:2761-2767. [PMID: 29112701 DOI: 10.1093/annonc/mdx406] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/08/2023] Open
Abstract
Background Combination pertuzumab, trastuzumab, and docetaxel (D) is considered standard first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. This post hoc, exploratory analysis of CLEOPATRA study data evaluated the clinical effects of D treatment duration within this regimen. The clinical benefits of pertuzumab and trastuzumab by different durations of D treatment were also evaluated. Patients and methods Patients with HER2-positive metastatic breast cancer received trastuzumab and D plus pertuzumab or placebo. Clinical outcomes were analyzed by the number of D cycles that patients received (<6D, 6D, or >6D). Progression-free survival (PFS) and overall survival (OS) for each treatment arm within each D cycle group were estimated using the Kaplan-Meier approach. Time-dependent, multivariate Cox regression was applied to estimate adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for HER2-targeted therapy and D cycle groups. Results Overall, 804 patients received <6D (n = 119), 6D (n = 210), or >6D (n = 475) cycles. After adjusting for pertuzumab benefits versus placebo (PFS HR = 0.61, 95% CI 0.51-0.74, P < 0.0001; OS HR = 0.60, 95% CI, 0.49-0.74, P < 0.0001), >6D versus 6D cycles was not associated with statistically significant improvements in PFS (HR = 0.80, 95% CI 0.63-1.01, P = 0.0640) or OS (HR = 0.88, 95% CI 0.69-1.12, P = 0.3073). Consistent improvements in PFS and OS were observed with pertuzumab versus placebo, irrespective of D duration. The HRs for PFS were 0.395, 0.615, and 0.633 for <6D, 6D, and >6D cycles, respectively (P < 0.05 for all D cycle groups). Corresponding HRs for OS were 0.577, 0.700, and 0.612, respectively (P < 0.05 for <6D and >6D). Conclusions After accounting for pertuzumab benefits, more than six cycles of D treatment was not associated with significant improvements in either PFS or OS compared with six cycles. The addition of pertuzumab to trastuzumab improved clinical outcomes versus trastuzumab plus placebo, regardless of D treatment duration. ClinicalTrials.gov identifier NCT00567190.
Collapse
Affiliation(s)
- D Miles
- Department of Medical Oncology, Mount Vernon Cancer Centre, Northwood, UK;.
| | - Y-H Im
- Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
| | | | - B Yoo
- Biostatistics, Genentech Inc., South San Francisco, USA
| | - A Knott
- Clinical Development, Roche Products Ltd, Welwyn Garden City, UK
| | - S Heeson
- Clinical Development, Roche Products Ltd, Welwyn Garden City, UK
| | | | - S M Swain
- Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, USA
| |
Collapse
|
29
|
Maes D, Bowen S, Fung A, Saini J, Bloch C, Egan A, Zeng J, Rengan R, Wong T. Dose Comparison between Proton Pencil Beam and Monte Carlo Dose Calculation Algorithm in Lung Cancer Patients. Int J Radiat Oncol Biol Phys 2017. [DOI: 10.1016/j.ijrobp.2017.06.2275] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
30
|
Chandra N, Nadra I, Ding L, Hardiman S, Fung A, Aymong E, Chan A, Hodge S, Antonsen J, Horgan K, Levin A, Robinson S, Della Siega A, Iqbal B. 3123The impact of renal disease on target vessel revascularisation following percutaneous coronary intervention: a contemporary analysis of 45,287 patients from the British Columbia Cardiac Registry. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx504.3123] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
31
|
Dehghani P, Tan M, Mehta S, Fisher H, Cantor W, Cheema A, Dery J, Welsh R, Lavi S, Kokis A, Cieza T, Ducas J, Kassam S, Brass N, Kim H, Fung A, Wang T, Bagai A, Goodman S. CLOPIDOGREL VERSUS NOVEL P2Y12 INHIBITOR USE IN FIBRINOLYSIS TREATED ST SEGMENT ELEVATION MYOCARDIAL INFARCTION: INSIGHTS FROM THE CANADIAN OBSERVATIONAL ANTIPLATELET STUDY (COAPT). Can J Cardiol 2016. [DOI: 10.1016/j.cjca.2016.07.172] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
32
|
Rodbard HW, Seufert J, Aggarwal N, Cao A, Fung A, Pfeifer M, Alba M. Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin. Diabetes Obes Metab 2016; 18:812-9. [PMID: 27160639 PMCID: PMC5089595 DOI: 10.1111/dom.12684] [Citation(s) in RCA: 46] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/21/2016] [Revised: 04/11/2016] [Accepted: 05/01/2016] [Indexed: 01/14/2023]
Abstract
AIMS To evaluate the efficacy and safety of titrated canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus (T2DM) inadequately controlled on metformin and sitagliptin. METHODS In this randomized, double-blind study, patients with T2DM (N = 218) on metformin ≥1500 mg/day and sitagliptin 100 mg received canagliflozin 100 mg or placebo. After 6 weeks, the canagliflozin dose was increased from 100 to 300 mg (or from placebo to matching placebo) if all of the following criteria were met: baseline estimated glomerular filtration rate ≥70 ml/min/1.73 m(2) ; fasting self-monitored blood glucose ≥5.6 mmol/l (≥100 mg/dl); and no volume depletion-related adverse events (AEs) within 2 weeks before dose increase. Endpoints included change in glycated haemoglobin (HbA1c) at week 26 (primary); proportion of patients achieving HbA1c <7.0%; and changes in fasting plasma glucose (FPG), body weight and systolic blood pressure (SBP). Safety was assessed using AE reports. RESULTS Overall, 85.4% of patients were titrated to canagliflozin 300 mg or matching placebo (mean ± standard deviation time to titration 6.2 ± 0.8 weeks). At week 26, canagliflozin (pooled 100 and 300 mg) demonstrated superiority in HbA1c reduction versus placebo (-0.91% vs. -0.01%; p < 0.001). Canagliflozin provided significant reductions in FPG, body weight and SBP compared with placebo (p < 0.001). The overall AE incidence was 39.8 and 44.4% for canagliflozin and placebo, respectively. Canagliflozin was associated with an increased incidence of genital mycotic infections. CONCLUSIONS Titrated canagliflozin significantly improved HbA1c, FPG, body weight and SBP, and was generally well tolerated over 26 weeks in patients with T2DM as add-on to metformin and sitagliptin.
Collapse
Affiliation(s)
- H W Rodbard
- Endocrine and Metabolic Consultants, Rockville, MD, USA
| | - J Seufert
- Department of Endocrinology and Diabetology, Clinic for Internal Medicine II, University Medical Center, Freiburg, Germany
| | - N Aggarwal
- Aggarwal and Associates Ltd, Brampton, ON, Canada
| | - A Cao
- Janssen Research & Development, LLC, Raritan, NJ, USA
| | - A Fung
- Janssen Research & Development, LLC, Raritan, NJ, USA
| | - M Pfeifer
- Janssen Scientific Affairs, LLC, Raritan, NJ, USA
| | - M Alba
- Janssen Research & Development, LLC, Raritan, NJ, USA
| |
Collapse
|
33
|
Fung A. SU-F-T-264: VMAT QA with 2D Radiation Measuring Equipment Attached to Gantry. Med Phys 2016. [DOI: 10.1118/1.4956474] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
34
|
|
35
|
Miles D, Fung A, Yoo B, Knott A, Heeson S, Portera C, Swain S. Abstract P4-14-27: Effect of docetaxel duration on clinical outcomes: Results from the phase III trial CLEOPATRA. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p4-14-27] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction:
In the CLEOPATRA study, pertuzumab (P) plus trastuzumab (T) and docetaxel (D) significantly improved median progression-free survival (PFS) and overall survival (OS) compared with placebo (Pla) plus T and D in pts with HER2-positive metastatic breast cancer. Study treatment was given every 3 weeks until disease progression (PD) or unacceptable toxicity. D starting dose was 75 mg/m2 and could be escalated or reduced per protocol. A minimum of 6 cycles of D was recommended. If D was discontinued, patients could continue P+T or Pla+T. To evaluate the potential association between D duration and clinical outcomes, we conducted post hoc exploratory analyses of the CLEOPATRA study.
Methods:
As of 11 Feb 2014 data cutoff, the safety population analyzed included 804 pts (396 Pla+T+D; 408 P+T+D) who received at least one dose of any study medication. Exposure and clinical outcomes of study treatment groups are presented by dichotomized subgroup of pts who received <6 cycles of D and those who received more than 6 cycles. Median PFS and OS were estimated using Kaplan-Meier methods. Cox regression analyses were used to estimate hazard ratios (HRs).
Results:
The median number of D cycles received was 8 for both arms. Forty-one % of pts received <6 (14% <6; 27% exactly 6) and 59% received >6 cycles.
Docetaxel Duration and Clinical Outcomes D <6 cycles (n=329, 41%)D >6 cycles (n=475, 59%) Pla+T+D (n=159)aP+T+D (n=170)aPla+T+D (n=237)P+T+D (n=238)Treatment Exposure#D Cycle, median (range)6 (1,6)6 (1,6)10 (7,42)10 (7,52)# Study Treatment Cycle, median (range)7 (1,78)14 (1,90)19 (7,92)28 (7,96)Duration of Study Treatment in month, median (range)6 (1,54)10 (1,63)14 (5,67)19 (5,68)Clinical OutcomesPFS in month, median (range)8.2 (6.2,9.0)12.5 (10.5,20.7)14.5 (12.6,17.2)22.8 (17.7,N/A)95% CIHR=0.59 (0.44,0.79)HR=0.65 (0.50,0.84)OS in month, median (range)29.8 (22.2,39.2)48.9 (36.8,N/A)46.7 (39.4,53.0)N/A (56.4,N/A)95% CIHR=0.67 (0.45,0.90)HR=0.62 (0.47,0.81)N/A=not available aTwo pts in each group had missing D cycle
Treatment Discontinuation Summary D <6 cyclesD >6 cycles Pla+T+D (n=159)P+T+D (n=170)Pla+T+D (n=237)P+T+D (n=238)D discontinuation before stopping anti-HER2 agents (n,%)90 (57)118 (69)180 (76)196 (82)Reason (n,%) AE/intercurrent illness34 (38)27 (23)60 (33)72 (37)Patient reasonb3 (3)5 (4)5 (3)8 (4)Standard practice36 (40)59 (50)65 (36)41 (21)Adequate therapy12 (13)22 (19)36 (20)59 (30)Other1 (1)1 (1)9 (5)11 (6)Missing4 (4)4 (3)5 (3)5 (3)Discontinuation of all study treatment (T+D+Pla or P), n159170237238Reason (n,%) AE/intercurrent illness15 (9)22 (13)25 (11)32 (13)Death10 (6)5 (3)4 (2)2 (1)Disease progression111 (70)110 (65)182 (77)154 (65)Patient reasonb17 (11)16 (9)12 (5)14 (6)Other6 (4)16 (9)12 (5)35 (15)Missing0 (0)1 (1)2 (1)1 (1)bIncluded failure to return, refused treatment, withdrawal, protocol violation
Conclusions:
Consistent with the overall study results, addition of P to T+D showed significant improvement in clinical outcomes regardless of whether <6 or >6 cycles of D were received. In the poster, three subgroup (<6, 6 and >6 D cycles) analyses and time-dependent Cox regression analysis to capture the dynamic variations in D exposure will be presented.
Citation Format: Miles D, Fung A, Yoo B, Knott A, Heeson S, Portera C, Swain S. Effect of docetaxel duration on clinical outcomes: Results from the phase III trial CLEOPATRA. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P4-14-27.
Collapse
Affiliation(s)
- D Miles
- Mount Vernon Cancer Center, Northwood, United Kingdom; Genentech, Inc., South San Francisco, CA; Roche Products Ltd., Welwyn Garden City, United Kingdom; Washington Cancer Institute, MedStar Washington Hospital Center, Washington, DC
| | - A Fung
- Mount Vernon Cancer Center, Northwood, United Kingdom; Genentech, Inc., South San Francisco, CA; Roche Products Ltd., Welwyn Garden City, United Kingdom; Washington Cancer Institute, MedStar Washington Hospital Center, Washington, DC
| | - B Yoo
- Mount Vernon Cancer Center, Northwood, United Kingdom; Genentech, Inc., South San Francisco, CA; Roche Products Ltd., Welwyn Garden City, United Kingdom; Washington Cancer Institute, MedStar Washington Hospital Center, Washington, DC
| | - A Knott
- Mount Vernon Cancer Center, Northwood, United Kingdom; Genentech, Inc., South San Francisco, CA; Roche Products Ltd., Welwyn Garden City, United Kingdom; Washington Cancer Institute, MedStar Washington Hospital Center, Washington, DC
| | - S Heeson
- Mount Vernon Cancer Center, Northwood, United Kingdom; Genentech, Inc., South San Francisco, CA; Roche Products Ltd., Welwyn Garden City, United Kingdom; Washington Cancer Institute, MedStar Washington Hospital Center, Washington, DC
| | - C Portera
- Mount Vernon Cancer Center, Northwood, United Kingdom; Genentech, Inc., South San Francisco, CA; Roche Products Ltd., Welwyn Garden City, United Kingdom; Washington Cancer Institute, MedStar Washington Hospital Center, Washington, DC
| | - S Swain
- Mount Vernon Cancer Center, Northwood, United Kingdom; Genentech, Inc., South San Francisco, CA; Roche Products Ltd., Welwyn Garden City, United Kingdom; Washington Cancer Institute, MedStar Washington Hospital Center, Washington, DC
| |
Collapse
|
36
|
Yang B, Fung A, Pac-Soo C, Ma D. Vascular surgery-related organ injury and protective strategies: update and future prospects. Br J Anaesth 2016; 117:ii32-ii43. [DOI: 10.1093/bja/aew211] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/30/2023] Open
|
37
|
Sra S, Goodman S, Lavi S, Dery J, Tan M, Fisher H, Zhang X, Zhu Y, Welsh R, Kokis A, Dehghani P, Cieza T, Fung A, Schampaert E, Mehta S, Yan A. ISCHEMIC AND BLEEDING EVENTS IN CANADIAN PATIENTS WITH MYOCARDIAL INFARCTION UNDERGOING PERCUTANEOUS CORONARY INTERVENTION WHO REQUIRE ORAL ANTICOAGULATION: INSIGHTS FROM THE CANADIAN OBSERVATIONAL ANTIPLATELET STUDY (COAPT). Can J Cardiol 2015. [DOI: 10.1016/j.cjca.2015.07.594] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
38
|
Ramanathan K, Abel J, Fung A, Fradet G, Della-Siega A, Wong D, Ding L, Park J, Gao M, Hennessy C, Taylor C, Farkouh M. TRANSLATING CLINICAL TRIAL RESULTS INTO CLINICAL PRACTICE FOR PATIENTS WITH DIABETES AND MULTIVESSEL CORONARY ARTERY DISEASE IN BRITISH COLUMBIA: A POPULATION-BASED STUDY. Can J Cardiol 2015. [DOI: 10.1016/j.cjca.2015.07.141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
39
|
Bode B, Stenlöf K, Harris S, Sullivan D, Fung A, Usiskin K, Meininger G. Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes. Diabetes Obes Metab 2015; 17:294-303. [PMID: 25495720 DOI: 10.1111/dom.12428] [Citation(s) in RCA: 166] [Impact Index Per Article: 18.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/22/2014] [Revised: 11/21/2014] [Accepted: 12/10/2014] [Indexed: 01/10/2023]
Abstract
AIMS The long-term efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, was evaluated over 104 weeks in patients aged 55-80 years with type 2 diabetes mellitus (T2DM) inadequately controlled on a stable antihyperglycaemic agent regimen. METHODS In this randomized, double-blind, phase III study, patients received canagliflozin 100 or 300 mg or placebo once daily during a 26-week core period (N = 714) and a 78-week extension period (n = 624). Efficacy endpoints at week 104 included change from baseline in glycated haemoglobin (HbA1c), fasting plasma glucose (FPG) and systolic blood pressure, and percent change from baseline in body weight and fasting plasma lipids. Safety was assessed by adverse event (AE) reports. RESULTS At week 104, canagliflozin 100 and 300 mg were associated with reductions in HbA1c versus placebo (-0.32 and -0.43% vs 0.17%, respectively; overall mean baseline, 7.7%) and more patients achieved HbA1c <7.0% with canagliflozin 100 and 300 mg than with placebo (35.8 and 41.9% vs 20.3%, respectively). Reductions in FPG, body weight and systolic blood pressure, and increases in high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) were seen with canagliflozin compared with placebo. The overall incidence rates of AEs over 104 weeks were 88.0, 89.8 and 86.1% with canagliflozin 100 and 300 mg and placebo, respectively; serious AE rates were low across treatment groups. The incidence rates of urinary tract infections, genital mycotic infections and osmotic diuresis- and volume depletion-related AEs were higher with canagliflozin than with placebo. CONCLUSION Canagliflozin improved glycaemic control, reduced body weight and systolic blood pressure, and was generally well tolerated in patients aged 55-80 years with T2DM over 104 weeks.
Collapse
Affiliation(s)
- B Bode
- Atlanta Diabetes Associates, Atlanta, GA, USA
| | | | | | | | | | | | | |
Collapse
|
40
|
Fung A, Zhang R, Boone R, Chan A, Della Siega A, Townley R, Kmetic A, Ding L. DETECTION, EXTENT, AND TEMPORAL TRENDS OF OBSTRUCTIVE CORONARY ARTERY DISEASE AMONG PATIENTS UNDERGOING ELECTIVE CARDIAC CATHETERIZATION IN BRITISH COLUMBIA. Can J Cardiol 2014. [DOI: 10.1016/j.cjca.2014.07.091] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
41
|
Kajander OA, Koistinen LS, Eskola M, Huhtala H, Bhindi R, Niemela K, Jolly SS, Sheth T, Sheth T, Jolly S, Kassam S, Vijayraghavan R, Lavi S, Bhindi R, Niemela K, Kajander O, Fung A, Cheema A, Alexopoulos D, Kocka V, Cantor W, Stankovic G, Dzavik V, Della Siega A. Feasibility and repeatability of optical coherence tomography measurements of pre-stent thrombus burden in patients with STEMI treated with primary PCI. Eur Heart J Cardiovasc Imaging 2014; 16:96-107. [DOI: 10.1093/ehjci/jeu175] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/03/2023] Open
|
42
|
Ghazizadeh S, Foss EW, Didier R, Fung A, Panicek DM, Coakley FV. Musculoskeletal pitfalls and pseudotumours in the pelvis: a pictorial review for body imagers. Br J Radiol 2014; 87:20140243. [PMID: 25096891 DOI: 10.1259/bjr.20140243] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
Many musculoskeletal abnormalities in the pelvis are first seen by body imagers while reviewing pelvic cross-sectional studies, and some of these abnormalities may mimic malignancy or another aggressive process. This article describes nine musculoskeletal pseudotumours and interpretative pitfalls that may be seen on CT, MRI and ultrasound imaging of the pelvis. Awareness of these pitfalls and pseudotumours may help avoid misdiagnosis and prevent inappropriate intervention or management.
Collapse
Affiliation(s)
- S Ghazizadeh
- 1 School of Medicine, Oregon Health and Science University, Portland, OR, USA
| | | | | | | | | | | |
Collapse
|
43
|
Manouzi A, Hosking MC, Fung A, De Souza A, Potts JE, Harris KC. Optical Coherence Tomography to Assess for Coronary Allograft Vasculopathy in Pediatric Transplant Recipients. Can J Cardiol 2013. [DOI: 10.1016/j.cjca.2013.07.114] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|
44
|
Manouzi A, Hosking MC, Fung A, De Souza A, Potts JE, Harris KC. Coronary Artery Abnormalities Identified With Optical Coherence Tomography in Children With Kawasaki Disease. Can J Cardiol 2013. [DOI: 10.1016/j.cjca.2013.07.115] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|
45
|
|
46
|
Fung A, Brearley Messer L. Tooth wear and associated risk factors in a sample of Australian primary school children. Aust Dent J 2013; 58:235-45. [PMID: 23713646 DOI: 10.1111/adj.12055] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2012] [Revised: 10/14/2012] [Accepted: 10/15/2012] [Indexed: 11/26/2022]
Abstract
BACKGROUND Anecdotally, tooth wear is increasing, perhaps attributable to diet. The irreversible surface loss may result in sensitivity and loss of form and function. Little data exist on the prevalence of tooth wear in Australian children. This study investigated consumption of potentially erosive foods and drinks, examining the prevalence, distribution of tooth wear and associations in a sample of children. METHODS Parents of 350, 6-12-year-olds reported their child's oral hygiene, dietary intake, medical and dental histories; 154 children (subsample) were examined. Associations were studied with single and multivariable analyses. RESULTS Tooth wear was parentally reported for 17% (59 children of the study population) and observed in 66% (102 of the subsample), particularly affecting primary teeth. Significant risk factors for parentally reported tooth wear were: consuming 2-4 cups soft drink/day (OR = 9.52), citrus flavoured sweets/gums ≥1/day (5.10), citrus fruits 1-2/wk (4.28); tooth grinding (5.32); medical condition present (2.48); male gender (2.80). Drinking 2-4 cups fruit juice/day was a significant risk factor for both parentally reported (3.23) and observed tooth wear (3.97). CONCLUSIONS Tooth wear appeared under-reported as some parents were unaware their child's teeth were affected. Significant risk factors for tooth wear were identifiable from children's histories. Risk factors should be addressed early so that tooth wear in the primary dentition does not affect permanent teeth.
Collapse
Affiliation(s)
- A Fung
- Melbourne Dental School, The University of Melbourne, Victoria
| | | |
Collapse
|
47
|
Kim A, Fung A, Davidson M. Predicting Dose in the Periphery of Intensity Modulated Radiation Therapy Treatment Fields. Int J Radiat Oncol Biol Phys 2012. [DOI: 10.1016/j.ijrobp.2012.07.2030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
48
|
Fung A, Yang CY, Freire S, Montemagno C, Brough B, Ho CM, Gu F, Shi W. Fluorescent Detection of Oral Pathogens by a Solid-Phase Immunoassay on PDMS. Conf Proc IEEE Eng Med Biol Soc 2012; 2005:2630-3. [PMID: 17282778 DOI: 10.1109/iembs.2005.1617009] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
We have developed an array of sensors for the oral pathogen Streptococcus mutans (S. mutans) using an enzymelinked linked immunosorbent assay (ELISA) on a polydimethylsiloxane (PDMS) device. The model bacterial analyte, S. mutans, has been implicated in the initiation and progression of dental caries. The PDMS was modified with 3-aminopropyltriethoxysilance (APTS) and glutaraldehyde to covalently crosslink monoclonal anti-S. mutans immunoglobulin G (IgG) to the sensor surface. Successful IgG immobilization was verified by AFM and fluorescence imaging. Colloidal bacteria were captured on the sensor surface and labeled with immuno-active quantum dots (QDs), whose fluorescence was excited by an LED and detected by a CCD. The system was capable of detecting S. mutans concentrations as low as 6 10<sup>6</sup>cells/ml in a 20 μl sample. This work represents a stable foundation for the development of a chair side diagnostic system capable of specific and sensitive detection of pathogens directly from oral fluid.
Collapse
Affiliation(s)
- A Fung
- Dept. of Bioengineering, UCLA, Los Angeles, CA 90095 USA
| | | | | | | | | | | | | | | |
Collapse
|
49
|
Cheung R, Fung A, Daljevic T, Safi M, Ogaki C, Mital S. 349 Assessing the Impact of Genetic Variation in Islet-1 on Congenital Heart Disease Subtypes. Can J Cardiol 2012. [DOI: 10.1016/j.cjca.2012.07.312] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
50
|
Poulter R, Lim I, Wood D, Saw J, Fung A, Hamburger J. 296 Morphometric Assessment of Coronary Artery Stenoses Using Optical Coherence Tomography Compared to Fractional Flow Reserve In Patients With Stable Chest Pain Versus Acute Coronary Syndromes. Can J Cardiol 2012. [DOI: 10.1016/j.cjca.2012.07.278] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|